



HAL
open science

Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.

Stanislas Pol, Clovis Luzivika Nzinga, H el ene Fontaine, Fabrice Carrat

► To cite this version:

Stanislas Pol, Clovis Luzivika Nzinga, H el ene Fontaine, Fabrice Carrat. Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.. *Alimentary Pharmacology & Therapeutics (Suppl)*, 2021, 53 (5), pp.659. 10.1111/apt.16251 . hal-03776245

HAL Id: hal-03776245

<https://hal.sorbonne-universite.fr/hal-03776245>

Submitted on 13 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1
2
3 **Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated**
4 **with Tenofovir or Entecavir - new clues from Europe. Authors' reply**
5
6
7
8
9
10

11 In their Editorial Lampertico and Papatheodoridis wisely conclude that the controversy of
12 whether Tenofovir reduces the risk of hepatocellular carcinoma to a greater extent than
13 does Entecavir treatment continues, leaving open the possibility that Tenofovir should be
14 the preferred agent in a subset of patients (1). From our data, we cannot exclude such a
15 proposition. However, in our comprehensive investigation, an analysis of the effect in
16 numerous subgroups (including in cirrhotic, non-cirrhotic, experienced or naïve patients,
17 compensated cirrhotics or cirrhotics with prior complications including HCC or non-
18 carcinoma complications) did not show evidence of any significant difference between these
19 antiviral therapies. (2). We believe that the recently published systematic review and meta-
20 analysis, including 119,053 patients, adds credible supplementary confirmation of the
21 absence of any major clinically significant difference between these two antiviral drugs: the
22 8 studies matched by propensity score report a 5-year cumulative incidence of
23 hepatocellular carcinoma of 3.44% for Entecavir and 3.39% for Tenofovir. In their analysis
24 the authors suggest that “treatment should be guided by patient tolerability and
25 affordability rather than whether one drug is more effective than the other” and we
26 completely agree with this conclusion.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Prof. Stanislas POL, MD;^{1,2} Clovis LUZIVIKA NZINGA , PhD,³ H el ene FONTAINE, MD,² Prof.
45 Fabrice CARRAT, PhD,^{3,4} for the French ANRS CO22 Hepather cohort

46
47
48 ¹ Universit  de Paris ; INSERM U-1223, Institut Pasteur, Paris, France.

49
50
51 ²Assistance Publique - H opitaux de Paris, H opital Cochin, Unit  d’H epato logie, Paris, France.

52
53
54 ³ Sorbonne Universit , Institut National de la sant  et de la Recherche M dicale, Institut
55 Pierre Louis d’Epid miologie et de Sant  Publique, Paris, France.

56
57
58 ⁴ Assistance Publique - H opitaux de Paris, H opital Saint-Antoine, Unit  de Sant  Publique,
59 Paris, France.
60

- 1
2
3
4
5
6 1. Lampertico P, Patheodoridis G. Editorial: similar risk of hepatocellular carcinoma in
7 chronic hepatitis B patients treated with Tenofovir or Entecavir - new clues from
8 Europe. *Aliment Pharmacol Ther* 2020; in press.
- 9
10
11 2. Pol S, Luzivika Nzinga C, Dorival C, et al. Impact of NUCs on HCC occurrence in HBV
12 chronic infection in the AFEF/ANRS CO22 Hepather cohort. *Aliment Pharmacol Ther*
13 2020 ; in press.
- 14
15
16 3. Tseng C-H, Hsu Y-C, Chen T-H, et al. Hepatocellular incidence with tenofovir versus
17 entecavir in chronic hepatitis B : a systematic review and meta-analysis. *Lancet*
18 *Gastroenterol Hepatol* 2020 ; 5 (12) : 1039-1052.
- 19
20
21
22
23
24
25

26 The author' declarations of personal and financial interests are unchanged from those in the
27 original article (2).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60